In line with the ESC mission, newly presented content is made available to all for a limited time (4 months for ESC Congress, 3 months for other events). ESC Professional Members, Association Members (Ivory & above) benefit from year-round access to all the resources from their respective Association, and to all content from previous years. Fellows of the ESC (FESC), and Professionals in training or under 40 years old, who subscribed to a Young Combined Membership package benefit from access to all ESC 365 content from all events, all editions, all year long. Find out more about ESC Memberships here.
The efficacy of nicorandil for patients with ischemic chronic heart failure
Authors : FG Batar (Sibiu,RO), S Batar (Sibiu,RO), R Mitea (Sibiu,RO), I Bitea (Sibiu,RO), G Eminovici (Sibiu,RO), M Teodoru (Sibiu,RO), I Manitiu (Sibiu,RO)
FG Batar1
,
S Batar2
,
R Mitea2
,
I Bitea3
,
G Eminovici2
,
M Teodoru2
,
I Manitiu2
,
1County Hospital, Cardiology - Sibiu - Romania
,
2Lucian Blaga University - Sibiu - Romania
,
3County Hospital, CVAIC Centre - Sibiu - Romania
,
Citation:
BACKGRAUND Nicorandil, combination of nitrate component and sarcolemmal adenosine triphosphate-sensitive potassium channel opener, is a potent vasodilator of coronary and peripheral vessels and has been used as an antianginal agent, but its effect in heart failure (HF) patients has not been fully established. Therefore, we examined impacts of nicorandil in ischemic HF patients in a small cohort.
PURPOSE To assess the efficacy of therapy with nicorandil in hospitalized with ischemic chronic heart failure.
METODS 12 HF patients with ischemic etiology were prospectively registered and divided into 2 groups based on oral administration of nicorandil during hospitalization : nicorandil group (n = 6) and non-nicorandil group (n=6). Patients were randomly assigned to be treated with or without oral nicorandil. BNP levels were measured at admission and at 5th day. Echocardiography was performed and the patients undergo cardiopulmonary exercise test.
RESULTS 66,6% of the patients were men, mean age was 67 years and mean length of inpatient stay was 7.8 days. We found a positive correlation between initial BNP and the number of hospitalized days in nicorandil group (r=0.64) and a negative correlation between initial BNP and the number of hospitalized days in non-nicorandil group (r=-0.73). The difference between levels of BNP after 5 days of treatment and initial BNP in the two groups is statistically significant (p=0.038). Ventilatory efficiency (VE/Vco2) is significantly different between the two groups (p=0.022).
Conclusion: The patients in the nicorandil group had higher decrease of BNP levels without shortening the length of hospitalization. Further studies with larger cohorts are needed.
In line with the ESC mission, newly presented content is made available to all for a limited time (4 months for ESC Congress, 3 months for other events). ESC Professional Members, Association Members (Ivory & above) benefit from year-round access to all the resources from their respective Association, and to all content from previous years. Fellows of the ESC (FESC), and Professionals in training or under 40 years old, who subscribed to a Young Combined Membership package benefit from access to all ESC 365 content from all events, all editions, all year long. Find out more about ESC Memberships here.
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.
Our mission: To reduce the burden of cardiovascular disease
